Abstract 17832: Is Regadenoson Ready for Prime Time in Cardiac Rubidium82 PET/CT Stress Imaging?
Introduction: Regadenoson is a selective A2A agonist which has been introduced as new pharmacological stress agent for cardiac myocardial perfusion imaging with a large experience using Single Photon Emission Computed Tomography thallium and technetium. There are no published observations of its use with cardiac Positron Emission Tomography/Computed Tomography (PET/CT) scan.
Hypothesis: We assessed the hypothesis that regadenoson is comparable to dipyridamole for detection of perfusion defect/s, ejection fraction (EF) and transient ischemic dilatation (TID) when used for cardiac PET/CT Rubidium (Rb) 82 rest/stress imaging.
Methods: A total of 894 patients who underwent rest/stress regadenoson Rb 82 PET/CT at our institute were screened. One hundred six patients received both rest/dipyridamole and rest/regadenoson PET/CT Rb 82 stress imaging with a mean time interval of 659 days between studies. Patients with interval cardiac events or intervention were excluded. General demographics and rest/stress imaging Results were collected including rest/stress perfusion defect/s, EF, and TID.
Results: The perfusion defects were mismatched in 10%. The pre-stress imaging EF in the dipyridamole and regadenoson studies did not show a significant difference (paired t-test 0.827). However, the post-stress EF was higher in the dipyridamole study compared to the regadenoson (paired t-test 0.024). Means for rest/stress/difference in dipyridamole EF were 60%/67%/9% while means for rest/stress/difference in regadenoson EF were 60%/65%/7%. Mean TID was 1.07 following regadenoson.
Conclusions: We conclude that the ability to detect perfusion defect/s are comparable using regadenoson or dipyridamole in cardiac Rb 82 PET/CT scans. The EF change from rest to stress during regadenoson scan is less compared to dipyridamole scan.
- © 2010 by American Heart Association, Inc.